Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
